# Tempest Therapeutics (TPST) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TPST
## Company Profile
- Ticker: TPST
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 0.7926 USD
- Market cap: 19397166.07 USD
- Last updated: 2026-10-05
## Business Overview
### In Vivo CAR T Company
Tempest Therapeutics develops next-generation CAR T therapies for autoimmune diseases and cancer. Its platform is designed to generate therapeutic CAR T cells directly inside the body using targeted mRNA and lipid nanoparticles.
### CD7-Targeted Delivery
Tempest's proprietary delivery system targets CD7-positive T cells with an mRNA/LNP payload. This approach is intended to avoid ex vivo manufacturing and make immune-reset treatment more broadly accessible.
### TPST-4003
TPST-4003 combines the in vivo delivery platform with a dual CD19/BCMA CAR construct to drive broad B-cell-lineage depletion and immune reset. Initial development targets myasthenia gravis and multiple sclerosis through a partner-led investigator study in China.
### TPST-2003
TPST-2003 is an ex vivo dual CD19/BCMA CAR T therapy in development for relapsed or refractory multiple myeloma, including patients with extramedullary disease. Tempest is preparing a potentially registrational clinical study.
## Why The Stock Is Moving

As of Oct 5, 2026, TPST closed down 2.29% at $0.7926. No new same-company headline was identified in the current news window.

## Future Catalysts

- First patient enrollment and dosing with TPST-4003 in the fourth quarter of 2026.
- Initiation of a potentially registrational TPST-2003 study in relapsed or refractory multiple myeloma in 2026.
- Initial clinical data from the TPST-4003 investigator study in the first half of 2027.

## Drug Assets

- TPST-2003

## Recent News
- 2026-09-23 12:00 EST — [Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors](https://biopharmsignal.com/news/TPST/tempest-appoints-global-finance-leader-nancy-freda-smith-to-board-of-directors-5706aa19) — Source: Tempest Therapeutics
- 2026-09-15 20:05 EST — [Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform](https://biopharmsignal.com/news/TPST/tempest-secures-exclusive-option-to-license-clinical-stage-cd7-targeted-lentivir-62c61795) — Source: Tempest Therapeutics
- 2026-09-11 12:00 EST — [Tempest Therapeutics Announces Up to $7.5 Million Private Placement](https://biopharmsignal.com/news/TPST/tempest-therapeutics-announces-up-to-7-5-million-private-placement-f8e123bc) — Source: Tempest Therapeutics
- 2026-09-08 12:30 EST — [Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/TPST/tempest-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conferenc-7f3b571f) — Source: Tempest Therapeutics
- 2026-08-13 20:26 EST — [Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/TPST/tempest-reports-second-quarter-2026-financial-results-and-provides-business-upda-0ee44cdb) — Source: Tempest Therapeutics